We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0QNV market cap is 556.75M. The company's latest EPS is CHF -0.0573 and P/E is -17.28.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Revenue | 2.76M | 3.61M | 2.92M | 1.42M | 1.61M |
| Operating Income | -14.6M | -12.24M | -15.51M | -20.52M | -10.28M |
| Net Income | -14.78M | -12.86M | -15.35M | -20.8M | -10.56M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Assets | 33.03M | 20.18M | 22.54M | 8.28M | 4.64M |
| Total Liabilities | 7.51M | 5.57M | 5.61M | 3.37M | 3.5M |
| Total Equity | 25.52M | 14.61M | 16.93M | 4.91M | 1.15M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Operating | -9.48M | -12.18M | -14.71M | -16.44M | -7.99M |
| Investing | -43k | -59k | -30k | 3k | -7k |
| Financing | -464k | 46k | 16.4M | 3.1M | 5.27M |
| Market Cap | 556.75M |
| Price to Earnings Ratio | -17.28 |
| Price to Sales Ratio | 113.79 |
| Price to Cash Ratio | 47.14 |
| Price to Book Ratio | 159.4 |
| Dividend Yield | - |
| Shares Outstanding | 184.35M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 3.02 |
| 52 Week Low | 3.02 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Addex Therapeutics Ltd |
| Address |
12 chemin des aulx geneva 1228 |
| Website | https://www.addextherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
